BioStock: Great interest in Dicot’s LIB-01

Many interested parties are keeping an eye on the development of LIB-01, Dicot's drug candidate for the treatment of erectile dysfunction, and the interest only seem to increase. At least if you ask the company's CEO, Elin Trampe, who BioStock talked to in connection with the Sexual Medicine Society of North America's annual conference.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/great-interest-in-dicots-lib-01/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se